New SPC referral to the CJEU on the interpretation of Art 3(a) and (c) for combination products (Merck v Clonmel)
The IPKat
MARCH 7, 2022
Furthermore, the primary inventive contribution of the patent was the disclosure of ezetimibe, and not its combined use with simvastatin. However, neither is it necessary that the product in some way corresponds to the "core inventive concept" of the patent.
Let's personalize your content